Online inquiry

IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (CAT#: GTTS-WQ1776MR)

This product GTTS-WQ1776MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL2RA gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.

Specifications
Product type	mRNA
Modified bases	N1-Methylpseudo-UTP
5' Cap	Cap 1
Species	Homo sapiens
RefSeq	NM_000417.3
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	3559
UniProt ID	P01589

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1776MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ8711MR	IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 2-Thio-UTP, 120 nt-poly(A))	mRNA	HuMax-TF-ADC
GTTS-WQ6665MR	IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 1, Pseudo-UTP, 30 nt-poly(A))	mRNA	DMUC5754A
GTTS-WQ9614MR	IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))	mRNA	JNJ-63723283
GTTS-WQ7432MR	IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, Pseudo-UTP, 30 nt-poly(A))	mRNA	GBR500
GTTS-WQ10662MR	IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, 2-Thio-UTP, 30 nt-poly(A))	mRNA	LY-3819253
GTTS-WQ2764MR	IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 2-Thio-UTP, 120 nt-poly(A))	mRNA	AMG162
GTTS-WQ10436MR	IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	LY-2495655
GTTS-WQ14364MR	IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	r-hTBP-1

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST